Currently, there is a lack of pathological landmarks to describe the progression of prion disease in vivo. Our goal was to use an experimental model to determine the temporal relationship between the transport of misfolded prion protein (PrP Sc ) from the brain to the retina, the accumulation of PrP Sc in the retina, the response of the surrounding retinal tissue, and loss of neurons. Retinal samples from mice inoculated with RML scrapie were collected at 30, 60, 90, 105, and 120 days post inoculation (dpi) or at the onset of clinical signs of disease (153 dpi). Retinal homogenates were tested for prion seeding activity. Antibody staining was used to assess accumulation of PrP Sc and the resulting response of retinal tissue. Loss of photoreceptors was used as a measure of neuronal death. PrP Sc seeding activity was first detected in all samples at 60 dpi. Accumulation of PrP Sc and coincident activation of retinal glia were first detected at 90 dpi. Activation of microglia was first detected at 105 dpi, but neuronal death was not detectable until 120 dpi. Our results demonstrate that by using the retina we can resolve the temporal separation between several key events in the pathogenesis of prion disease. 
. 1 During progression of TSEs, like many protein misfolding disorders, transport of misfolded protein from one central nervous system (CNS) structure seeds protein misfolding and accumulation in another. 2 The details underlying this series of events that begins with the arrival of misfolded protein in a CNS structure and ends with neuronal death in that structure are not well understood. Seeding the brain with an inoculum of misfolded prion protein induces TSEs; thus, these diseases provide a unique opportunity to study the transport of PrP Sc from one CNS structure to another.
Currently, there is no treatment for TSEs. Although in silico and in vitro approaches have been effective at identifying compounds with therapeutic potential, 3e8 development of effective therapies would be facilitated by a well-described in vivo model of misfolded protein transport and accumulation, with objective measures of neural degeneration.
The retina is part of the CNS and is affected by numerous protein misfolding diseases, including Alzheimer disease, cervids, 15e17 bovine spongiform encephalopathy in cattle, 18, 19 and Creutzfeldt-Jakob disease in humans. 20, 21 The retina and associated visual structures provide an excellent model to study the transport of misfolded proteins from one CNS structure to another. 22 Herein, we report the time course of transport of misfolded prion protein to the retina after inoculation into the brain in a mouse model of scrapie. We describe the temporal separation between the first detection of misfolded prion protein at 40% of the 153-day incubation period, the accumulation of PrP Sc at 60% of the incubation period, the activation of microglia at 70% of the incubation period, and the loss of retinal neurons at 80% of the incubation period. Thus, we provide a well-described in vivo model that can be used to study the pathogenesis of disease and to assess the potential effectiveness of therapeutic approaches against the spread and accumulation of misfolded prion protein.
Materials and Methods

Ethics Statement
The experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals. 23 The protocol was approved by the Institutional Animal Care and Use Committee at the National Animal Disease Center (protocol number 3985). Sample size was determined statistically using preliminary data from clinically affected animals.
Animals and Tissue Preparation
C57Bl/6 mice, aged 6 to 8 weeks, were inoculated with a brain homogenate containing mouse-adapted Rocky Mountain Laboratories (RML) scrapie via intracranial injection into the right cerebral hemisphere at the level of the temporal bone. Tissue collection occurred at 30, 60, 90, 105, and 120 days post inoculation (dpi), along with another group composed of animals exhibiting clinical signs approximately 155 dpi. For each time point, there were two groups of age-matched negative control mice: a mock-inoculated group that was inoculated with brain homogenate from healthy mice and a noninoculated group that received no inoculation (five to six animals were included in each group). Globes were collected into Bouin's fixative for 24 hours and post-fixed in 10% formalin until processing. Tissues were then embedded in paraffin, divided into sections (4 mm thick), and affixed to slides for hematoxylin and eosin staining and immunolabeling.
Expression and Purification of rPrP Substrate
Recombinant prion protein (rPrP) used in RT-QuIC assay was expressed and purified using standard protocol from previous reports. 24, 25 Briefly, rPrP composed of the Syrian hamster residues 90 to 231 in pET vector with N-terminal histidine sequence was transformed in to Escherichia coli Rosetta2(DE3) cells. The cultures were grown under continuous selection with kanamycin and chloramphenicol in the Lysogeny broth media. The log phase cultures were scaled up with Overnight Express Autoinduction System 1 for protein induction. Later, the inclusion bodies were isolated from bacterial pellets using BugBuster Master Mix and were denatured in 8M guanidine hydrochloride. Later, the rPrP is bound to pre-equilibrated nickel-nitrilotriacetic acid superflow resin for 50 minutes. The beads were packed in Akta #XK26 column, and rPrP was purified using nickelnitrilotriacetic acid affinity chromatography on a Bio-Rad Duo flow system in a refrigerated room. On column refolding was performed using gradient dilution of guanidine hydrochloride over 5 hours. Pure rPrP was eluded from the column using imidazole binding with increasing linear gradient. Chilled dialysis buffer was added to the peak elude fractions, and dialyzed overnight against three changes of chilled dialysis buffer (10 mmol/L NaPO 4 , pH 5.8) after initial filtration. Protein concentration was determined using the extension coefficient and filtering through 100-kDa cutoff filters before subjecting to RT-QuIC assay. The quality of rPrP was confirmed by NMR and CD spectral analyses.
RT-QuIC Assay for Retina Samples
The RT-QuIC assay was performed using previously published protocols from published reports 24, 26, 27 with slight modifications. The reaction mixtures consisted of final concentrations of 350 mmol/L NaCl, 0.1 mmol/L EDTA, 10 mmol/ L thioflavin T, 0.1 mg/mL rPrP, and 0.002% SDS in 1Â phosphate-buffered saline. The retina samples from time course RML scrapie-infected mice were washed twice and homogenized using repeated pipetting and sonication in a cup sonicator with two pulses of 30 seconds. The clarified supernatants were normalized to protein concentration using Bradford protein assay. The reactions consisted of 5 mg of protein from retina homogenates that were used as seed. We included mouse brain homogenates (0.5 mg) from clinical RML scrapie infected mice, mock brain homogenates, and blank (buffer) as controls. All of the samples were run using a blinded study design (N.K., S.M., A.K.). The plates were sealed with Nalgene Nunc plate sealer and subjected to RT-QuIC assay. The plates were incubated at 42 C in Cytation3 (Biotek, Winooski, VT) plate reader with alternate cycles of 1-minute shake (double orbital) and rest. All of the samples were run in quadruplicates, and samples were judged to be positive as reported previously. 27 Average fluorescence readings of four replicates plus 10 times SD of negative controls were the criteria for determining the threshold. Recording of thioflavin T fluorescence (450 AE 15 nm excitation and 480 AE 10 nm emission) was noted every 30 minutes, and data analysis was performed using Biotek's Gen5 software version 2.07.17.
Immunohistochemistry
Paraffin-embedded tissues were analyzed using immunohistochemistry. After deparaffinization and rehydration, tissue
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The American Journal of Pathology -ajp.amjpathol.orgsections were autoclaved for 20 minutes in an antigen retrieval solution (DAKO Target Retrieval Solution; Dako Corp., Carpinteria, CA). Mouse anti-PrP (6C2; CVI-WUR, Lelystad, Neth) was diluted 1:2000. Rabbit anti-glial fibrillary acidic protein (GFAP) (Dako Corp.) was diluted at 1:10,000. Slides were incubated in primary antibodies 6C2 overnight at 4 C and GFAP for 24 hours at room temperature and 72 hours at 4 C. Immunoreactivity was developed using Envision þ Dual Link System-horseradish peroxidase (Dako Corp.) with diaminobenzidene (Vector Labs, Peterborough, UK), and slides were counterstained with hematoxylin. Images were captured using a Nikon DS camera on a Nikon Eclipse 50i microscope. For immunofluorescence detection of CD68 immunoreactivity (1:100; Dako Corp.), slides were incubated with Cy3 conjugated AffiniPure secondary antibodies (1:300; Jackson ImmunoResearch, West Grove, PA) for 1.5 hours and counterstained with DAPI (1 mg/mL; Sigma-Aldrich, St. Louis, MO). Immunofluorescence images were captured using a commercial upright microscope system (Zeiss AxioPlan 2 Microscope Imaging System; Oberkochen, Germany).
CD68 immunoreactivity was quantified using ImageJ analysis software version 1.49v (http://imagej.nih.gov/ij; NIH, Bethesda, MD), and was expressed as a percentage of the total image area (outer limiting membrane to inner limiting membrane of the central retina) using constant thresholds. Values at each time point were pooled and analyzed with oneway analysis of variance and Tukey's post hoc test using Prism 6 for Windows (Graph Pad Software, San Diego, CA).
Assessment of Neuronal Loss
Thinning of the outer nuclear layer was measured by counts of cell bodies spanning the layer. For each cross section, three counts were made in the central retina and averaged into a single value for each animal. Data were analyzed with one-way analysis of variance using Dunnett's multiple comparison test.
Results
Incubation Period
Seventeen C57Bl/6 mice were used to determine the incubation period of mouse-adapted (RML) scrapie. The average incubation period was 153 dpi, with a SD of 1.4 days. On the basis of a 153-day incubation period, tissues were assayed at 19.6% of total incubation (30 dpi), 39.2% of total incubation (60 dpi), 58.8% of incubation (90 dpi), 68.6% of incubation (105 dpi), 78.4% of incubation (120 dpi), and 100% of incubation period (clinical illness).
PrP
Sc Seeding Activity Is Detected in the Retina at Approximately 40% of Incubation
The real-time quaking induced conversion (RT-QuIC) assay was used to determine the time course of misfolded prion protein transport from the brain to the retina. Seeding activity in the RT-QuIC assay was noted in all replicates (both biological and technical) of clinical, 120 dpi, 90 dpi, and 60 dpi retina samples but not in retinas from mock inoculated animals or from 30 dpi inoculated retina samples ( Figure 1A ). Seeding activity in retinal samples was comparable to the RML scrapie infected brain homogenate ( Figure 1A) . When data were expressed as amyloid formation rate [the inverse of the time for the thioflavin T fluorescence signals to cross the threshold (in hours)], it demonstrated that amyloid formation rate is proportional to the incubation period. That is, the longer the course of the disease, the greater the rate of amyloid formation ( Figure 1B) . The mean rate of amyloid formation from retina of 30, 60, 90, and 120 dpi and clinical were 0, 0.06, 0.12, 0.17, and 0.14 hours À1 , respectively.
PrP Sc Immunoreactivity Is Detected in the Retina at Approximately 60% of Incubation Period
Immunohistochemistry was used to assess PrP Sc accumulation in retinal sections from mice at 30, 60, 90, 105, and 120 dpi and at the time clinical illness was observed (Figure 2 ). Mock-infected animals (collected at the same time points) were used as controls. There was no immunostaining for PrP Sc in any of the control animals ( Figure 2A ). Immunostaining was first observed at 90 dpi (at approximately 60% Figure 1 PrP Sc seeding activity in the retinas from scrapie-inoculated mice. Seeding activity is detected at 60 dpi and all subsequent time points. A: Each trace represents average data from three biological samples, each run in quadruplicate. B: When seeding activity is expressed as amyloid formation rate (AFR), it demonstrates that amyloid formation is proportional to incubation period. BH, brain homogenate; BLK, blank well; Neg, negative; Pos, positive. ajp.amjpathol.org -The American Journal of Pathology of the total incubation period) in multifocal photoreceptor inner segments throughout the retinal sections of each mouse examined ( Figure 2B ). Fifteen days later, at 105 dpi, immunoreactivity in photoreceptor inner segments was more widespread, and PrP Sc immunoreactivity also was observed in the outer plexiform (synaptic) layer ( Figure 2C ). At 120 dpi, PrP
Sc immunoreactivity was observed in the inner plexiform layer in addition to the photoreceptor layer and outer plexiform layer ( Figure 2D ). At the time of clinical disease (approximately 153 dpi), PrP Sc immunoreactivity was observed in the inner and outer plexiform layers and in the photoreceptors that remained ( Figure 2E ) (although by this time point, most photoreceptors had been lost).
Activation of Müller Glia Accompanies Early Detection of PrP
Sc at 60% of the Incubation Period
Müller glia are radial glial cells that are derived from retinal progenitor cells. 28 Quiescent Müller glia are immunoreactive for GFAP in their end feet, which are in the optic fiber layer. Under conditions of retinal stress, activated Müller glia have GFAP immunoreactivity more widely distributed in their processes that span from the optic fiber layer to the outer limiting membrane. 29 Immunohistochemistry with an antibody against GFAP was used to assess activation of Müller glia in retinal sections from 30, 60, 90, 105, and 120 dpi and at the stage of clinical illness (Figure 3 ). Mock-inoculated animals collected at each time point were used as controls. In control animals, GFAP immunoreactivity was observed in the optic fiber layer ( Figure 3A ) that contains astrocytes and the end feet of Müller glia. There was not an appreciable difference between GFAP immunoreactivity in mock, 30 dpi, or 60 dpi (data not shown). However, GFAP immunoreactivity at 90 dpi was observed in processes of Müller glia that extended as far as the outer plexiform layer ( Figure 3B ). At 105 dpi, GFAP immunoreactivity was more robust, but still only observed between the optic fiber layer and the outer plexiform layer ( Figure 3C ). GFAP immunoreactivity at 120 dpi also was Sc immunoreactivity is absent from the retinas of mock-inoculated mice (A) and all mice examined before 90 dpi. B: At 90 dpi, PrP Sc immunoreactivity is observed in occasional photoreceptor inner segments in all mice examined (arrows). C: By 105 dpi, PrP Sc immunoreactivity is consistently observed in photoreceptor inner segments and in the outer plexiform layer. D: A similar but more widespread distribution is observed at 120 dpi. E: Widespread loss of photoreceptors from the outer nuclear layer (ONL) is observed in the retinas from mice with clinical disease. In these mice, PrP
Sc immunoreactivity is observed primarily in the outer plexiform layer (OPL) and inner plexiform layer (IPL). GCL, ganglion cell layer; INL, inner nuclear layer. Scale bar Z 10 mm (AeE). observed in the outer nuclear layer and reached the outer limiting membrane in some areas ( Figure 3D ). At the clinical stage of disease, there was severe loss of photoreceptors and Müller glia hypertrophy with GFAP immunoreactivity observed throughout the thickness of the retina ( Figure 3E ).
Activation of Microglia Is Detected in the Retina at 70% of Incubation Period
An antibody against CD68 was used to assess activation of microglia in retinal sections from mice at dpi 30, 60, 90, 105, 120, and the clinical stage of disease in comparison to mock-inoculated control animals. Rare, multifocal CD68 immunoreactivity was observed in the outer plexiform layer of control retinal sections ( Figure 4A ). CD68 immunoreactivity in retinal sections from mice examined at 30 or 60 dpi (data not shown) or 90 dpi ( Figure 4B ) was not appreciably different from controls. However, at 105 dpi, CD68 immunoreactivity was more intense and widespread in the outer plexiform layer and also was observed multifocally in the inner plexiform layer and the optic fiber layer ( Figure 4C ). Immunoreactivity was further increased at 120 dpi ( Figure 4D ). In retinal sections from clinically ill mice, CD68 immunoreactivity was most intense in the optic fiber layer and the inner plexiform layer ( Figure 4E ). When CD68 immunoreactivity was quantified at each time point, it illustrated that the first significant increase in CD68 immunoreactivity compared to control animals was at the 105 dpi time point (P < 0.05) ( Figure 4F ) or at approximately 70% of incubation period.
Neuronal Death Does Not Occur until 80% of Incubation Period
To determine the time course of photoreceptor loss during RML scrapie incubation, outer nuclear layer thickness (as measured by number of photoreceptor cell nuclei) was assessed at 30, 60, 90, 105, and 120 dpi and in the retinas from animals with clinical disease ( Figure 5 ). In noninoculated control animals and mock-inoculated animals, the mean outer nuclear layer thickness was 11.05 cell nuclei (AE0.81). The mean outer nuclear layer thickness was not appreciably different from controls at 30, 60, 90, or 105 dpi. At 120 dpi, however, the average outer nuclear layer thickness was significantly decreased to 8.94 (AE1.00) cell nuclei (P < 0.01) and decreased to an average of 2.08 (AE0.50) cell nuclei thick in retinas from animals with clinical disease. Thus, neuronal death in the form of significant photoreceptor loss (P < 0.01) was not detected in the retinas until approximately 80% of total incubation period.
Discussion
Prion Seeding Activity Is Detected in the Retina Relatively Early in Disease Incubation
Our results demonstrate seeding activity by RT-QuIC in the retina at 60 dpi (approximately 40% of incubation period) in all samples assayed. Prion seeding activity in the retina was detected 30 days before the detection of PrP Sc via immunohistochemistry. This is consistent with a report that Figure 4 Activation of microglia in retinas from scrapie-inoculated mice. CD68 immunoreactivity was used to assess microglial activation. CD68 immunoreactivity is barely detectable in mock-inoculated animals (A) or retinas from animals at 90 dpi (B). C: There is an observed increase in CD68 immunoreactivity at 105 dpi that is localized primarily to the outer plexiform layer (OPL). CD68 immunoreactivity increases at 120 dpi (D) and in clinical retinas (E), where it is observed in both the outer and inner plexiform layers as well as the optic fiber layer. F: Quantification of CD68 immunoreactivity illustrates the increase that was first detected at 105 dpi, is greater at 120 dpi, and greatest in retinas from clinically ill animals. Data are presented as means AE SD (F). *P < 0.05, ***P < 0.001, and ****P < 0.0001 versus mock. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bar Z 10 mm (AeE).
compared RT-QuIC with immunohistochemistry and found RT-QuIC could detect prion seeding activity in tissues that were negative by immunohistochemistry. 30 In the current study, the next earliest time point was 30 dpi; thus, arrival of misfolded prion protein was between 30 and 60 dpi. Because the retina is spatially distinct from the brain, where the inoculum was delivered, we are confident that the seeding activity detected is a result of transport, presumably retrograde transport via the optic nerve 31 ; however, here we cannot entirely rule out transport by the circulatory system, as infectious prion protein was likely in blood of these animals before its detection in retina. 32 Rapid retrograde transport of PrP Sc in motor tracts, on the order of 6 weeks, has been previously reported after inoculation of the sciatic nerve. 33 The consistent appearance of prion seeding activity in retinas at 60 dpi may suggest widespread distribution, albeit at a lower level than detected by traditional diagnostic 
Neuronal Loss Does Not Occur until Late in the Disease Incubation Period
Herein, we report widespread loss of photoreceptors in the retinas of mice with scrapie. This result is consistent with other rodent models of TSE, including a hamster model of transmissible mink encephalopathy 35, 36 and mouse models of scrapie 37 or Creutzfeldt-Jakob disease. 38 Our results demonstrate, however, that loss of these retinal neurons does not occur until approximately 80% of the incubation period, despite the fact that prion-seeding activity was detected in the retina at 40% of the incubation period. This observation is Figure 5 Thickness of outer nuclear layer in scrapie-inoculated mice.
Outer nuclear layer (ONL) thickness is expressed as number of cell bodies spanning the thickness of the layer. Outer nuclear layer thickness is not different from mock-inoculated controls at 30, 60, 90, or 105 dpi. Outer nuclear layer thickness decreases in the retinas at 120 dpi and the retinas from animals with clinical illness. Data are presented as means AE SD. **P < 0.01, ****P < 0.0001 versus control.
Figure 6 Summary of PrP
Sc transport and scrapie pathogenesis in the mouse retina. The incubation period of RML scrapie in C57Bl/6 mice in this study was 153 days. PrP Sc seeding activity was first observed at 60 dpi, approximately 40% of the incubation period. PrP Sc immunoreactivity and activation of retinal glia were first detected at 90 dpi, which is approximately 60% of the incubation period. At 105 dpi, or approximately 70% of the incubation period, activation of microglia was detected. Evidence of neuronal death in the outer nuclear layer was not detected until 120 dpi, at approximately 80% of the incubation period of RML scrapie in C57Bl/6 mice. consistent with prior work demonstrating an increase in prion infectivity before the development of neuropathology. 34 
Temporal Separation of Key Events in Prion Disease
Our results demonstrate the temporal separation of several key events in the pathogenesis of prion disease beginning with the transport of misfolded prion protein from the brain to the retina (Figure 6 ). The sequence of events described herein is not unexpected. However, by determining the time lag between these events in vivo (eg, the lag between PrP Sc accumulation and cell death), we have provided concrete criteria that can be used not only to assess the effectiveness of anti-prion compounds, 39 but also to determine the stage of disease that a given compound would be most effective. For example, evaluation of an anti-prion compound in mice infected with RML scrapie between 60 and 90 dpi could provide information about the ability of the compound to attenuate accumulation of PrP Sc after misfolded prion protein has been detected in the tissue. Similarly, evaluation of an immunomodulatory or neuroprotective compound between 90 and 120 dpi could provide key information about the relationship between activated microglia and neuronal death in prion disease. 4 The results reported herein contribute to a sizable body of work describing the time course of prion disease. A great deal has been done to identify early biomarkers of disease in cattle, 40e42 cervids, 43, 44 primates, 45 sheep, 46 and rodent models of TSEs. 34, 47 The retina is a tissue that is spatially separated from the rest of the brain, has a relatively simple organization, and can be readily assessed using rapid and noninvasive techniques. This work provides a timeline for key pathologic milestones of prion disease in the retina and a model to study mechanisms of disease progression and evaluate therapeutic interventions.
